Влияние показателей минимальной остаточной болезни на риск развития рецидива у пациентов с острым лимфобластным лейкозом

Минимальная остаточная болезнь (МОБ) – наиболее значимый прогностический фактор риска развития рецидива у пациентов с острым лимфобластным лейкозом (ОЛЛ). Оценка МОБ необходима не только для прогноза рецидива заболевания, но и для дополнительной стратификации пациентов на группы риска с целью индивидуализации терапии и оценки ее качества. В данном исследовании проведен анализ показателей МОБ у пациентов с ОЛЛ на 15-й и 36-й день индукционной терапии, а также оценено их влияние на показатели выживаемости и риск развития рецидива у пациентов с ОЛЛ, получающих лечение согласно протоколу ОЛЛ-МБ 2008.

1. The childhood leukemia international consortium / C. Metayer [et al.] // Cancer Epidemiol. – 2013. – Vol. 37, N 3. – P. 336–347. https://doi.org/10.1016/j.canep.2012.12.011

2. Childhood and adolescent cancer statistics, 2014 / E. Ward [et al.] // CA: а Cancer J. Clin. – 2014. – Vol. 64, N 2. – P. 83–103. https://doi.org/10.3322/caac.21219

3. Belson, M. Risk factors for acute leukemia in children: a review / M. Belson, B. Kingsley, A. Holmes // Environ. Health Perspect. – 2007. – Vol. 115, N 1. – P. 138–145. https://doi.org/10.1289/ehp.9023

4. Cools, J. Improvements in the survival of children and adolescents with acute lymphoblastic leukemia / J. Cools // Haematologica. – 2012. – Vol. 97, N 5. – P. 635. https://doi.org/10.3324/haematol.2012.068361

5. Pui, C. H. Acute lymphoblastic leukemia / C.-H. Pui, W. E. Evans // N. Engl. J. Med. – 1998. – Vol. 339, N 9. – P. 605–615. https://doi.org/10.1056/NEJM199808273390907

6. Cooper, S. L. Treatment of pediatric acute lymphoblastic leukemia / S. L. Cooper, P. A. Brown // Pediatr. Clin. North Am. – 2015. – Vol. 62, N 1. – P. 61–73. https://doi.org/10.1016/j.pcl.2014.09.006

7. How I treat relapsed childhood acute lymphoblastic leukemia / F. Locatelli [et al.] // Blood. – 2012. – Vol. 120, N 14. – P. 2807–2816. https://doi.org/10.1182/blood-2012-02-265884

8. Lee, J. W. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia / J. W. Lee, B. Cho // Korean J. Pediatr. – 2017. – Vol. 60, N 5. – P. 129–137. https://doi.org/10.3345/kjp.2017.60.5.129

9. Teachey, D. T. Predicting relapse risk in childhood acute lymphoblastic leukaemia / D. T. Teachey, S. P. Hunger // Br. J. Haematol. – 2013. – Vol. 162, N 5. – P. 606–620. https://doi.org/10.1111/bjh.12442

10. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia / G. Gaipa [et al.] // Cytometry B Clin. Cytom. – 2013. – Vol. 84, N 6. – P. 359–369. https://doi.org/10.1002/cyto.b.21101

11. Risk- and response-based classifcation of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) / K. R. Schultz [et al.] // Blood. – 2007. – Vol. 109, N 3. – P. 926–935. https://doi.org/10.1182/blood-2006-01-024729

12. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia / M. Lauten [et al.] // Haematologica. – 2012. – Vol. 97, N 7. – P. 1048–1056. https://doi.org/10.3324/haematol.2011.047613

13. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 / M. Schrappe [et al.] // Blood. – 2000. – Vol. 95, N 11. – P. 3310–3322.

14. Minimal residual disease in leukaemia patients / T. Szczepańsk [et al.] // Lancet Oncol. – 2001. – Vol. 2, N 7. – P. 409–417.

15. Campana, D. Determination of minimal residual disease in leukaemia patients / D. Campana // Br. J. Haematol. – 2003. – Vol. 121, N 6. – P. 823–838. https://doi.org/10.1046/j.1365-2141.2003.04393.x

16. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies / J. J. van Dongen [et al.] // Blood. – 2015. – Vol. 125, N 26. – P. 3996–4009. https://doi.org/10.1182/blood-2015-03-580027

17. Brüggemann, M. Has MRD monitoring superseded other prognostic factors in adult ALL? / M. Brüggemann, T. Raff, M. Kneba // Blood. – 2012. – Vol. 120, N 23. – P. 4470–4481. https://doi.org/10.1182/blood-2012-06-379040

18. Chatterjee, T. Minimal residual disease detection using flow cytometry: applications in acute leukemia / T. Chatterjee, R. S. Mallhi, S. Venkatesan // Med. J. Armed Forces India. – 2016. – Vol. 72, N 2. – P. 152–156. https://doi.org/10.1016/j.mjaf.2016.02.002

19. Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia / M. R. V. Ikoma [et al.] // Rev. Bras. de Hematol. Hemoter. – 2015. – Vol. 37, N 6. – P. 406–413. https://doi.org/10.1016/j.bjhh.2015.07.012

20. Campana, D. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia / D. Campana, C.-H. Pui // Blood. – 2017. – Vol. 129, N 4. – P. 1913–1918. https://doi.org/10.1182/blood-2016-12-725804

21. Campana, D. Molecular determinants of treatment response in acute lymphoblastic leukemia / D. Campana // Hematol. Am. Soc. of Hematol. Educ. Program. – 2008. – Vol. 2008, N 1. – P. 366–373. https://doi.org/10.1182/asheducation-2008.1.366

22. Clinical signifcance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study / M. J. Borowitz [et al.] // Blood. – 2008. – Vol. 111, N 12. – P. 5477–5485. https://doi.org/10.1182/blood-2008-01-132837

23. Clinical signifcance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group / H. Cavé [et al.] // N. Engl. J. Med. – 1998. – Vol. 339, N 9. – P. 591–598. https://doi.org/10.1056/NEJM199808273390904

24. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood / J. J. van Dongen [et al.] // Lancet. – 1998. – Vol. 352, N 9142. – P. 1731–1738. https://doi.org/10.1016/S0140-6736(98)04058-6

25. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group / O. Krejci [et al.] // Bone Marrow Transplant. – 2003. – Vol. 32, N 8. – P. 849–851. https://doi.org/10.1038/sj.bmt.1704241

26. Prognostic value of minimal residual disease quantifcation before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group / P. Bader [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, N 3. – P. 377–384. https://doi.org/10.1200/JCO.2008.17.6065

27. UKALL 2003, a randomised trial investigating treatment intensifcation for children and young adults with minimal residual disease defned high risk acute lymphoblastic leukaema / A. J. Vora [et al.] // Blood. – 2012. – Vol. 120, N 21. – P. 136.

28. Molecular response to treatment redefnes all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study / V. Conter [et al.] // Blood. – 2010. – Vol. 115, N 16. – P. 3206–3214. https://doi.org/10.1182/blood-2009-10-248146

29. Румянцев, А. Г. Результаты проспективных кооперированных исследований эффективности лечения рака у детей в России [Электронный ресурс] / А. Г. Румянцев // DOCPLAYER. – Режим доступа : https://docplayer.ru/91149045-Rezultaty-prospektivnyh-kooperirovannyh-issledovaniy-effektivnosti-lecheniya-raka-u-detey-v-rossii.html. – Дата доступа : 03.12.2018.